Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The economic implications of influenza vaccination for adults with asthma.

Trogdon JG, Nurmagambetov TA, Thompson HF.

Am J Prev Med. 2010 Nov;39(5):403-10. doi: 10.1016/j.amepre.2010.07.012.

PMID:
20965377
2.

Economic evaluation of influenza vaccination. Assessment for The Netherlands.

Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ.

Pharmacoeconomics. 1999;16 Suppl 1:33-40. Review.

PMID:
10623374
3.

Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies.

Madjid M, Naghavi M, Litovsky S, Casscells SW.

Circulation. 2003 Dec 2;108(22):2730-6. Review. No abstract available.

4.

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT.

Drugs. 2002;62(7):1013-24. Review.

PMID:
11985488
5.

[Economic prerequisites of active influenza prevention].

Grześk G, Gałaj A, Korbal P, Durmowicz A, Szadujkis-Szadurski L, Borys D, Grześk E.

Med Pr. 2002;53(4):329-32. Review. Polish.

PMID:
12474413
6.

Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.

Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ.

Am J Prev Med. 2006 Jul;31(1):72-9. Review.

PMID:
16777545
7.

Influenza infection and vaccination in pregnant women.

Tamma PD, Steinhoff MC, Omer SB.

Expert Rev Respir Med. 2010 Jun;4(3):321-8. doi: 10.1586/ers.10.26. Review.

PMID:
20524915
8.

[An economic evaluation of strategy for expanding influenza vaccination in Japan].

Hara Y.

Nihon Rinsho. 2003 Nov;61(11):2013-8. Review. Japanese.

PMID:
14619447
9.

Commentary: benefits of influenza vaccine in US elderly--new studies raise questions.

Glezen WP, Simonsen L.

Int J Epidemiol. 2006 Apr;35(2):352-3. Review. No abstract available.

10.

Evaluating the impact of influenza vaccination. A North American perspective.

Fedson DS.

Pharmacoeconomics. 1996;9 Suppl 3:54-61. Review.

PMID:
10160488
11.

[Influenza vaccination of children as a general factor in prevention of influenza epidemics].

Gendon IuZ.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):78-85. Review. Russian.

PMID:
17886380
12.

Influenza vaccine in patients with asthma.

Hanania NA, Atmar RL, Castro M.

Expert Rev Vaccines. 2006 Feb;5(1):111-8. Review.

PMID:
16451113
13.

Mitigation of pandemic influenza: review of cost-effectiveness studies.

Lugnér AK, Postma MJ.

Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):547-58. doi: 10.1586/erp.09.56. Review.

PMID:
19941432
14.

[Pharmaco-economics of anti-influenza vaccinations].

Jahnz-Rózyk K.

Pol Merkur Lekarski. 2003 Jun;14(84):679-81. Review. Polish.

PMID:
14524303
15.

Economic value of influenza vaccination.

de Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W.

Hum Vaccin Immunother. 2012 Jan;8(1):119-29. doi: 10.4161/hv.8.1.18420. Review.

PMID:
22251999
16.

Is there any evidence for influenza vaccination in children with asthma?

Carroll W, Burkimsher R.

Arch Dis Child. 2007 Jul;92(7):644-5. Review. No abstract available.

17.

Adjustment for continuous confounders: an example of how to prevent residual confounding.

Groenwold RH, Klungel OH, Altman DG, van der Graaf Y, Hoes AW, Moons KG; PROTECT WP2 (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium, Work Programme 2 [Framework for pharmacoepidemiology studies])..

CMAJ. 2013 Mar 19;185(5):401-6. doi: 10.1503/cmaj.120592. Review. No abstract available.

Items per page

Supplemental Content

Support Center